ATyr Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 04:57 pm EDT
Share
aTyr Pharma, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 12.42 million compared to USD 10.39 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.64 a year ago. Diluted loss per share from continuing operations was USD 0.44 compared to USD 0.64 a year ago.
For the six months, net loss was USD 24.57 million compared to USD 17.54 million a year ago. Basic loss per share from continuing operations was USD 0.88 compared to USD 1.16 a year ago. Diluted loss per share from continuing operations was USD 0.88 compared to USD 1.16 a year ago.
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
ATYR PHARMA, INC. 
